摘要
目的:探讨予米力农及卡维地洛联合治疗心力衰竭的临床疗效。方法:我院于2010年3月至2012年4月共收治心力衰竭患者40例,随机分成联合治疗组和常规对照组各20例,治疗组采用米力农及卡维地洛治疗,对照组采用常规抗心衰治疗。结果:联合治疗组与对照组相比,HR、CO、LVEF、E/A有较好的改善,高敏C反应蛋白(hs-CRP)和血浆脑钠肽前体(Pro-BNP)水平较对照组显著降低,P<0.05具有统计学意义。结论:米力农联合卡维地洛治疗心力衰竭临床疗效显著,值得临床推广。
Objective：Explore the clinical efficacy of combination therapy of milrinone and carvedilol in heart failure patients.Methods：Our hospital in March 2010 to April 2012 were treated 40 cases of heart failure patients,milrinone and carvedilol treatment were randomly divided into 20 cases of the combination therapy group and normal control group,treatment group and control group using conventional anti-heart failure treatment.Results：Combined treatment group compared with the control group,HR,CO,LVEF,E/A had a better improvement.High-sensitivity C-reactive protein（hs-CRP）,and plasma brain natriuretic peptide precursor（Pro-BNP） levels was lower than the control group,P0.05statistically significant.Conclusion：The combination treatment of milrinone and carvedilol has notable clinical curative effect on heart failure,and it is worthy of using widely in clinic.
出处
《中国医药导刊》
2012年第12期2150-2151,共2页
Chinese Journal of Medicinal Guide
关键词
米力农
卡维地洛
心力衰竭
临床疗效
Milrinone
Carvedilol
Heart failure
Clinical efficacy
